LMTK3 is implicated in endocrine resistance via multiple signaling pathways

Oncogene

Volumn 32, Issue 28, 2013, Pages 3371-3380

  Stebbing, J ^a   Filipovic, A ^a   Lit, L C ^a   Blighe, K ^b   Grothey, A ^a   Xu, Y ^a   Miki, Y ^c   Chow, L W ^c,d   Coombes, R C ^a   Sasano, H ^c   Shaw, J A ^b   Giamas, G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIMED Medical Institute   (Hong Kong)

Author keywords

Breast cancer; Endocrine resistance; Estrogen receptor; HSPB8; LMTK3; Oncogene

Indexed keywords

ENZYME; ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 22; LEMUR TYROSINE LINASE 3; PROTEIN TYROSINE KINASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; GENE SILENCING; HORMONAL THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE C MYC; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATOR GENE; TREATMENT FAILURE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ENDOCRINE SYSTEM; FEMALE; HEAT-SHOCK PROTEINS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84880268260     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.343     Document Type: Article

References (47)

1. CRUK. http://cancerhelp.cancerresearchuk.org/type/breast-cancer/2012.
2. Cordera F, Jordan VC. Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 2006; 33: 631-641.
3. Dixon JM, Rodger A, Stebbing J. Breast cancer (non-metastatic). Clin Evid 2005; 13: 2226-2257.
4. Stebbing J, Delaney G, Thompson A. Breast cancer (non-metastatic). Clin Evid 2007; 2007.
5. Stebbing J, Stearns V, Davidson NE. Role of CYP2D6 testing in selection of endocrine therapy for breast cancer. Pharmacogenomics 2007; 8: 1-3.
6. Schafer JM, Jordan VC. Models of hormone resistance in vitro and in vivo. Methods Mol Med 2006; 120: 453-464.
7. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
8. Giamas G, Man YL, Hirner H, Bischof J, Kramer K, Khan K et al. Kinases as targets in the treatment of solid tumors. Cell Signal 2010; 22: 984-1002.
9. Giamas G, Stebbing J, Vorgias CE, Knippschild U. Protein kinases as targets for cancer treatment. Pharmacogenomics 2007; 8: 1005-1016.
10. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011; 17: 715-719.
11. Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, Pearlberg J et al. Highthroughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci USA. 2011; 108: 2058-2063.
12. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y et al. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 120: 639-648.
13. Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008; 111: 13-17.
14. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012; 22: 220-231.
15. Lasfargues EY, Coutinho WG, Redfield ES. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 1978; 61: 967-978.
16. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009; 16: 413-424.
17. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010; 16: 214-218.
18. Paroni G, Fratelli M, Gardini G, Bassano C, Flora M, Zanetti A et al. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2011, epub ahead of print 08 November 2011.
19. Harrington WR, Sengupta S, Katzenellenbogen BS. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 2006; 147: 3843-3850.
20. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 3021-3031.
21. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 17: 2024-2034.
22. Guo S, RR Gonzalez-Perez. Notch, IL-1 and leptin crosstalk outcome (NILCO) is critical for leptin-induced proliferation, migration and VEGF/VEGFR-2 expression in breast cancer. PLoS One 2011; 6: e21467.
23. Rizzo P, Miao H, D0Souza G, Osipo C, Song LL, Yun J et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 68: 5226-5235.
24. Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME et al. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Res Treat 2009; 116: 263-271.
25. Tomura H, Mogi C, Sato K, Okajima F. Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. Cell Signal 2005; 17: 1466-1476.
26. Xu Y, Zhu K, Hong G, Wu W, Baudhuin LM, Xiao Y et al. Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1. Nat Cell Biol 2000; 2: 261-267.
27. Stone JC. Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells. Genes Cancer 2011; 2: 320-334.
28. Liguori L, Andolfo I, de Antonellis P, Aglio V, di Dato V, Marino N et al. The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. Cell Cycle 2012; 11: 569-581.
29. Wilson CG, Robert-Cooperman CE, Burkhardt BR. PANcreatic-DERived factor: novel hormone PANDERing to glucose regulation. FEBS Lett 2011; 585: 2137-2143.
30. Oshima T, Fujino T, Ando K, Hayakawa M. Role of FGD1, a Cdc42 guanine nucleotide exchange factor, in epidermal growth factor-stimulated c-Jun NH2- terminal kinase activation and cell migration. Biol Pharm Bull 2011; 34: 54-60.
31. Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G. Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 2011; 11: 417.
32. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 2008; 8: 154.
33. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the new kid on the PI3K block. Oncotarget 2011; 2: 321-328.
34. Fedele CG, Ooms LM, Ho M, Vieusseux J, O0Toole SA, Millar EK et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci USA. 2010; 107: 22231-22236.
35. Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol 2011; 25: 72-82.
36. Xu J, Wan M, He Q, Bassett Jr RL, Fu X, Chen AC et al. SGK3 is associated with estrogen receptor expression in breast cancer. Breast Cancer Res Treat 2012.
37. Sun X, Fontaine JM, Bartl I, Behnam B, Welsh MJ, Benndorf R. Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptorpositive breast cancer cells. Cell Stress Chaperones 2007; 12: 307-319.
38. Cook KL, Shajahan AN, Clarke R. Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther 2011; 11: 1283-1294.
39. Lange CA, Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 2011; 18: C19-C24.
40. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011; 29: 4452-4461.
41. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
42. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Ann Rev Med 2011; 62: 233-247.
43. Hu DG, Mackenzie PI. Estrogen receptor alpha, fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17beta-estradiol in MCF-7 cells. Mol Pharmacol 2009; 76: 425-439.
44. Kappe G, Franck E, Verschuure P, Boelens WC, Leunissen JA, de Jong WW. The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10. Cell Stress Chaperones 2003; 8: 53-61.
45. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006; 66: 3903-3911.
46. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
47. Stebbing J, Filipovic A, Ellis IO, Green AR, D0Silva TR, Lenz HJ et al. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 2012; 132: 537-544.